Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [ 11 C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D 2/3 receptor binding in the conscious monkey brain. A single infusion of esketamine (0.5 mg/kg), but not R-ketamine (0.5 mg/kg), caused a reduction of binding availability of dopamine D 2/3 receptor in the monkey striatum. This study suggests that unlike to R-ketamine, esketamine can cause dopamine release in the striatum, and that its release might be associated with psychotomimetic effects of esketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effect of esketamine and R-ketamine on the BPND of [11C]raclopride to dopamine D2/3 receptors in the striatum of conscious monkeys. a Representative photomicrographs of typical MRI and parametric PET images of [11C]raclopride to dopamine D2/3 receptors from vehicle (saline)-treated, esketamine (0.5 mg/kg, 40-min)-treated and R-ketamine (0.5 mg/kg, 40-min)-treated monkeys. PET images from 61 to 91 min were obtained. Color bar indicates a level of the non-displaceable binding potential (BPND) of [11C]raclopride. b The non-displaceable binding potential BPND of [11C]raclopride in the striatum. The data show the mean ± S.E.M. (n = 4). **P < 0.01 compared with vehicle (saline)-treated condition](https://figures.cochat.ai/paper-figures/20e6477afd9f436cbcaea3029ca73a7b/reduction-of-dopamine-d2-3-receptor-binding-in-the-striatum-after-a-single-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal studies, R-ketamine has been reported to have a rapid onset of antidepressant effects and a better side-effect profile than esketamine34–41”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Cited by
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“5 mg/kg for 40-min).(106) This positron emission tomography study suggests that (S)-ketamine-induced marked dopamine release from the presynaptic terminal may contribute to acute side-effects (i.”
BackgroundSelf-citationPharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“, increased dopamine tone) after intravenous injection of (S)-ketamine but not to (R)-ketamine [59].”
BackgroundIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
“Another important aspect is the apparent lower incidence of psychotomimetic effects with arketamine than with other forms, and it might be explained by its lower potential to produce dopamine release and reduction of parvalbumin-positive neurons when compared with esketamine as demonstrated in animal studies [16, 31].”
ResultAntidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationYang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Self-citationMolecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
“5 mg/kg), reduced the binding availability of the dopamine D2/3 receptor in the conscious monkey striatum [56], suggesting that esketamine, but not arketamine, can cause dopamine release in the striatum.”
BackgroundSelf-citationKokkinou, M., Ashok, A. H., & Howes, O. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.190 · Cited by 247
Ketamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine
Hashimoto, K. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113935 · Cited by 236
Self-citationYang, C., Qu, Y., Fujita, Y., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0031-4 · Cited by 223
Self-citationMicroglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01377-7 · Cited by 216
Self-citationMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citationChang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Self-citationA historical review of antidepressant effects of ketamine and its enantiomers
Wei, Y., Chang, L., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172870 · Cited by 157
Self-citationEsketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
Qu, Y., Yang, C., Ren, Q., Ma, M., Dong, C., & Hashimoto, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-16060-7 · Cited by 127
Self-citationEsketamine: Less Drowsiness, More Analgesia
Mion, G., & Himmelseher, S. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006851 · Cited by 136
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Self-citationAMPA Receptor Activation–Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine
Yang, C., Kobayashi, S., Nakao, K., Dong, C., Han, M., Qu, Y., Ren, Q., Zhang, J.-C., Ma, M., Toki, H., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.05.007 · Cited by 125
Self-citationZhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0733-x · Cited by 119
Self-citationShirayama, Y., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx108 · Cited by 111
Self-citationArketamine, a new rapid-acting antidepressant: A historical review and future directions
Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 99
Self-citationAgo, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz041 · Cited by 92
Self-citationChen, Y., Guo, Y., Wu, H., Tang, Y.-J., Sooranna, S. R., Zhang, L., Chen, T., Xie, X., Qiu, L., & Wu, X. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0953 · Cited by 91
Esketamine for Treatment-Resistant Depression: A Review of Clinical Evidence (Review)
Vasiliu, O. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11810 · Cited by 82
“…(S)‑norketamine, has been identified, which results from cytochrome P450 metabo‑ lization of its parent compound and possesses a notable affinity for NMDA receptors, higher than that of (R, S)‑ketamine and (S)‑ketamine [inhibitor constant (Ki)=1.7 µM vs. 0.53 µM and 0.3 µM, respectively] (7,8,22).”
InfluentialZanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80
Self-citationWitkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in Pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 72
Shirayama, Y., & Hashimoto, K. (2016) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0718-1 · Cited by 79
Self-citationEsketamine: new hope for the treatment of treatment-resistant depression? A narrative review
Salahudeen, M. S., Wright, C. M., & Peterson, G. M. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620937899 · Cited by 72
Ketamine’s antidepressant action: beyond NMDA receptor inhibition
Hashimoto, K. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1238899 · Cited by 68
Self-citationWang, X., Chang, L., Wan, X., Tan, Y., Qu, Y., Shan, J., Yang, Y., Ma, L., & Hashimoto, K. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105635 · Cited by 64
Self-citationKetamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 72
Self-citationNovel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Tian, Z., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.07.003 · Cited by 62
Self-citation(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Wang, X., Yang, J., & Hashimoto, K. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104762 · Cited by 63
Self-citationHashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 62
Self-citationZhang, J., Qu, Y., Chang, L., Pu, Y., & Hashimoto, K. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz048 · Cited by 55
“Importantly, the side effects of (R)-ketamine in rodents were less than those of (R,S)-ketamine and (S)-ketamine (Yang et al., 2015; Hashimoto et al., 2017; Tian et al., 2018a; Chang et al., 2019).”
BackgroundSelf-citationHashimoto, K. (2016) · Psychological Medicine · doi:10.1017/s0033291716000969 · Cited by 54
Self-citationLevinstein, M. R., Carlton, M. L., Di Ianni, T., Ventriglia, E. N., Rizzo, A., Gomez, J. L., Budinich, R. C., Shaham, Y., Airan, R. D., Zarate, C. A., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.12.019 · Cited by 53
Fujita, A., Fujita, Y., Pu, Y., Chang, L., & Hashimoto, K. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05346-5 · Cited by 56
Self-citationMa, L., Zhang, J., Fujita, Y., Qu, Y., Shan, J., Wan, X., Wang, X., Ishima, T., Kobayashi, K., Wang, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01803-6 · Cited by 57
Self-citationEap, C. B., Gründer, G., Baumann, P., Ansermot, N., Conca, A., Corruble, E., Crettol, S., Dahl, M., de León, J., Greiner, C., et al. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1878427 · Cited by 57
The neurophysiology of ketamine: an integrative review
McMillan, R. L., & Muthukumaraswamy, S. D. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0090 · Cited by 56
Zhang, K., Dong, C., Fujita, Y., Fujita, A., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx100 · Cited by 48
Self-citationWang, Y., Zhang, N., Liu, L., Jiang, H., Hu, D., Wang, Z., Chen, N., & Zhang, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.01.024 · Cited by 52
Xiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111904 · Cited by 49
Self-citationKetamine-dependent neuronal activation in healthy volunteers
Höflich, A. S., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Ganger, S., Spies, M., Windischberger, C., Kasper, S. F., Winkler, D., et al. (2016) · Brain Structure and Function · doi:10.1007/s00429-016-1291-0 · Cited by 50
(R)‐ and (S)‐ketamine induce differential fMRI responses in conscious rats
Masaki, Y., Kashiwagi, Y., Watabe, H., & Abe, K. (2019) · Synapse · doi:10.1002/syn.22126 · Cited by 44
Rafało-Ulińska, A., & Pałucha-Poniewiera, A. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113633 · Cited by 45
Tan, Y., Fujita, Y., Qu, Y., Chang, L., Pu, Y., Wang, S., Wang, X., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172839 · Cited by 45
Self-citationAn Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine
Berardis, D. D., Tomasetti, C., Pompili, M., Serafini, G., Vellante, F., Fornaro, M., Valchera, A., Perna, G., Volpe, U., Martinotti, G., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200131100316 · Cited by 47
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 44
Ma, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Wan, X., Fujita, Y., & Hashimoto, K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02192-6 · Cited by 45
Self-citationArketamine for cognitive impairment in psychiatric disorders
Hashimoto, K. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01570-5 · Cited by 43
Self-citationRecent advances in the study of anesthesia-and analgesia-related mechanisms of S-ketamine
Zhou, J., Peng, G., Liang, W., Chen, Z., Liu, Y., Wang, B., Guo, M., Deng, Y.-L., Jun-ming, Y., Zhong, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228895 · Cited by 46
Sucrose intake lowers μ-opioid and dopamine D2/3 receptor availability in porcine brain
Winterdahl, M., Noer, O., Orłowski, D., Schacht, A. C., Jakobsen, S., Alstrup, A. K. O., GJEDDE, A. H., & Landau, A. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-53430-9 · Cited by 49
Qu, Y., Shan, J., Wang, S., Chang, L., Pu, Y., Wang, X., Tan, Y., Yamamoto, M. P., & Hashimoto, K. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01208-w · Cited by 44
Self-citationMa, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Fujita, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109250 · Cited by 45
Self-citationHashimoto, K., Zhao, M., Zhu, T., Wang, X., & Yang, J. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.07.001 · Cited by 42
Self-citationBeyond Ketamine: New Approaches to the Development of Safer Antidepressants
Chaki, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170221101054 · Cited by 40
A bibliometric analysis of research on (R)-ketamine from 2002 to 2021
He, T., Wang, D., Wu, Z., Huang, C., Xu, X., Xu, X., Liu, C., Hashimoto, K., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109207 · Cited by 39
Self-citationXiong, Z., Chang, L., Qu, Y., Pu, Y., Wang, S., Fujita, Y., Ishima, T., Chen, J., & Hashimoto, K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172904 · Cited by 41
Self-citationIs (S)-norketamine an alternative antidepressant for esketamine?
Hashimoto, K., & Yang, C. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0922-2 · Cited by 37
Self-citationWitkin, J. M., Kranzler, J., Kaniecki, K., Popik, P., Smith, J. L., Hashimoto, K., & Sporn, J. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172927 · Cited by 38
Self-citationScotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 40
Gan, S.-L., Long, Y.-Q., Wang, Q., Feng, C.-D., Lai, C.-X., Liu, C., Ding, Y.-Y., Liu, H., Peng, K., & Ji, F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1128406 · Cited by 37
Pałucha-Poniewiera, A. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.02.011 · Cited by 36
Wang, Y. Y., Jiang, R., Wu, Z., Zhou, L., Xu, J., Huang, C., Yang, L., Zhu, B., Yan, E., Liu, C., et al. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173226 · Cited by 37
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Shafique, H. S., Demers, J. C., Biesiada, J., Golani, L. K., Cerne, R., Smith, J. L., Szostak, M., & Witkin, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126804 · Cited by 34
Zhang, K., Toki, H., Fujita, Y., Ma, M., Chang, L., Qu, Y., Harada, S., Nemoto, T., Mizuno‐Yasuhira, A., Yamaguchi, J., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5017-2 · Cited by 33
Self-citationInvestigational drugs for treating major depressive disorder
Dhir, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1267727 · Cited by 32
Zhang, K., Ma, M., Dong, C., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy065 · Cited by 30
Self-citationXiong, Z., Zhang, K., Ishima, T., Ren, Q., Chang, L., Chen, J., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.10.005 · Cited by 29
Self-citationvan de Loo, A. J. A. E., Bervoets, A. C., Mooren, L., Bouwmeester, N. H., Garssen, J., Zuiker, R., van Amerongen, G., van Gerven, J., Singh, J., der Ark, P. V., et al. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4706-6 · Cited by 29
Ketamine and Norketamine: Enantioresolution and Enantioselective Aquatic Ecotoxicity Studies
Pérez‐Pereira, A., Ribeiro, C. M. R., Teles, F. P. P., Gonçalves, R., Gonçalves, V. M. F., Pereira, J. A., Carrola, J. S., Pires, C. A. M., & Tiritan, M. E. (2020) · Environmental Toxicology and Chemistry · doi:10.1002/etc.4955 · Cited by 31
Chen, X., Wang, M., Hu, Y., Zhan, Y., Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhong, X., Li, H., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01221-z · Cited by 27
Beyond serotonin: newer antidepressants in the future
Rakesh, G., Pae, C., & Masand, P. S. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341310 · Cited by 29
Tan, Y., & Hashimoto, K. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.040 · Cited by 28
Self-citationFujita, Y., Hashimoto, Y., Hashimoto, H., Chang, L., & Hashimoto, K. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173954 · Cited by 27
Self-citation(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice
Wang, X., Chang, L., Tan, Y., Qu, Y., Shan, J., & Hashimoto, K. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.10.013 · Cited by 26
Self-citationMa, L., Wang, L., Qu, Y., Wan, X., & Hashimoto, K. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02564-6 · Cited by 28
Self-citationChang, L., Wei, Y., Qu, Y., Zhao, M., Zhou, X., Long, Y., & Hashimoto, K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106573 · Cited by 27
Self-citationDopaminergic impact of cART and anti-depressants on HIV neuropathogenesis in older adults
Matt, S. M., & Gaskill, P. J. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146398 · Cited by 27
Chang, L., Toki, H., Qu, Y., Fujita, Y., Mizuno-Yasuhira, A., Yamaguchi, J.-I., Chaki, S., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy053 · Cited by 25
Self-citationXu, D., Liu, G., Zhao, M., Wan, X., Qu, Y., Murayama, R., & Hashimoto, K. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.222 · Cited by 23
Self-citationTan, Y., Fujita, Y., Pu, Y., Chang, L., Qu, Y., Wang, X., & Hashimoto, K. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01365-6 · Cited by 22
Self-citationNew investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 23
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S., Xiong, Z., Shirayama, Y., & Hashimoto, K. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01012-1 · Cited by 20
Self-citationPeng, F., Fan, J., Ge, T., Liu, Q. Q., & Li, B. J. (2020) · Cell Proliferation · doi:10.1111/cpr.12804 · Cited by 20
Microglial BDNF modulates arketamine’s antidepressant-like effects through cortico-accumbal pathways
He, L., Wang, X., Luo, S., Jiang, N., Yan, Y., Xie, M., Chen, Y., Yang, C., Yao, W., Hashimoto, K., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv5986 · Cited by 18
Self-citationTian, Z., Dong, C., Zhang, K., Chang, L., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy072 · Cited by 18
Self-citationFujita, Y., & Hashimoto, K. (2020) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12132 · Cited by 20
Self-citationFlynn, L. T., & Gao, W. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02235-4 · Cited by 19
Galvanho, J. P., Manhães, A. C., Carvalho-Nogueira, A. C. C., Silva, J. D. M., Filgueiras, C. C., & Abreu‐Villaça, Y. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109775 · Cited by 17
Rapid Antidepressant Activity of Ketamine Beyond NMDA Receptor
Hashimoto, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-49795-2_4 · Cited by 17
Self-citationXiong, Z., Zhang, K., Ishima, T., Ren, Q., Ma, M., Pu, Y., Chang, L., Chen, J., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.11.010 · Cited by 17
Self-citationChen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats
Popik, P., Khoo, S. Y., Kuziak, A., Gołębiowska, J., Potasiewicz, A., Hogendorf, A. S., Popik, O., Matłoka, M., Moszczyński-Pętkowski, R., Nikiforuk, A., et al. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173011 · Cited by 14
Metadata
- Authors
- Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H.
- Affiliations
- Chiba University (JP)
- Hamamatsu Photonics (Japan) (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2016-04-18
- Volume
- 267
- Issue
- 2
- Pages
- 173-176
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC5323469
- OpenAlex
- W2337679024
- Cited by
- 127
- References
- 19
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 13 · 2021: 14 · 2020: 19 · 2019: 16 · 2018: 12 · 2017: 11 · 2016: 6
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24116006)
- Chiba University
- National Institutes of Health
- Japan Society for the Promotion of Science (24116006)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, (R)-ketamine, dopamine D2/D3 receptors, striatum, psychotomimetic effects, dopamine release, antidepressants, conscious monkeys
- MeSH terms
- Animals, Antidepressive Agents, Ketamine, Macaca mulatta, Male, Neostriatum, Receptors, Dopamine D2, Positron-Emission Tomography, Receptors, Dopamine D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.